试论品牌管理在制药业中的潜能

目的:发掘制药业品牌管理的潜能,探讨品牌管理在制药业中的重要性。方法:从制药业目前的环境入手,分析品牌管理的发展机遇。结果与结论:制药业的品牌管理面临前所未有的发展契机。随着产品时代的结束,品牌管理已成为制药业获得竞争优势的一项重要资源。     

化工工人肌肉骨骼功能及其与工作能力的关系

目的 研究化工工人肌肉骨骼功能状况及其与工作能力的关系。方法 对101名化工作业工人进行肌肉骨骼功能(背肌耐力、手握力、躯干柔韧性、腹肌力和肌肉骨骼功能指数)测定和工作能力指数(wAI)测定。结果男性握力显著高于女性(P＜O.01)，腹肌力、背肌耐力和肌肉骨骼功能指数(MSFI)均男性较高，躯干柔韧性女性较高；年龄与MSFI呈负相关(r=O．489，P＜O．01)，随年龄增加，肌肉骨骼功能下降；不同劳动类型化工职工肌肉骨骼功能差异无显著性；肌肉骨骼功能与工作能力之间存在密切的关系，MSFI与WAI的相关系数为O.215(P＜O．05)，MSFI分级和WAI分级间有较好的一致性，完全一致率为56．7％。结论 肌肉骨骼功能的测定对于评价化工工人工作能力可能具有重要的意义。     

某钢铁企业职业伤害调查研究

[目的]探讨某钢铁股份公司职业伤害的发生特点、分布、主要原因及发生趋势。[方法]根据对某钢铁股份公司1999年1月至2002年12月间职工人数及发生的职业伤害事故调查资料进行分析。[结果]该公司2002年职业伤害发生率为22．39／万，职业伤害类型以物体打击(24．39％)、灼烫(17．56％)、高处坠落(17．32％)和机械伤害(15．37％)为主。而操作不当(22．20％)和安全意识不强(15．85％)是其主要原因。[结论]职业伤害防制应从提高职工安全意识和技术水平着手，针对不同类型作业场所采取相应的措施。     

医院管理公司对中国医疗产业发展影响探讨

医院管理公司是继国有医院集团以后新兴的医院联合的模式,这种模式可以充分利用医疗产业现有的机会,通过产业集中和完善医院的治理结构,对当前的产业总体结构进行调整.医疗产业经过调整后,会产生新的产业分工,并通过市场调节机制发挥卫生资源重新配置的职能.     

探索制药工程本科专业培养方案新思路

对国内外大学制药工程专业进行了调研、考察，邀请校内有关专家进行多次论证，并通过培养方案的可行性答辩，认为制药工程人才应具备厚基础、宽口径、重实践的知识结构；课程体系设置为通识类、学科类与集中实践三部分。     

美国制药工程教育一瞥

美国的制药行业产值约占全球的三分之二 ,面对药物研发和生产制造过程的困难 ,企业兼并重组 ,研发战略正在改变。制药工程可望提高研发效率 ,优化生产制造过程 ,从而降低成本。制药工程教育可能是解决行业问题的理想方案     

β-环糊精包结芪玄益心胶囊中挥发油的实验研究

目的:研究β-环糊精包结芪玄益心胶囊中挥发油的最佳工艺条件.方法:通过正交设计分析方法进行多因素多水平试验,以挥发油利用率和含油率为考察指标,评定包结工艺的优劣.结果:搅拌法最佳包结工艺条件是水与β-环糊精的配比为1:4,油与β-环糊精的配比为1:6,包结时间为6h,包结温度为75℃.结论:β-环糊精包结工艺更有效地稳定挥发油的有效成分.     

Rational use of medicines – an important issue in pharmaceutical policy

In this article the authors deal with issues of drug utilisation from a clinical and policy perspective. They address the difficulties of managing drug therapy on a population level, which is known among professionals, as the problem of rational use of medicines. Various definitions and interpretations are presented and compared. This is followed by a presentation of the concerns associated with pharmaceutical marketing from a policy perspective, including the fear that the dominance of information produced by industry may lead to irrational drug use. Next, the authors review the tools for policy making including educational, managerial, and regulatory interventions. The (often overlapping) concepts of medicines management, clinical pharmacy and pharmaceutical care are then discussed to show how professionals, sometimes in collaboration with policymakers, have tackled the problem of nonrational use of medicines. The authors address the question as to whether the rational use of medicines a universal concept, whether it can be and whether it should be? They argue that, as with most concepts, the rational use of medicines must always be viewed in context. They conclude that pharmacy needs to adapt its way of thinking to include the issue of context. They point out that clinical pharmacists today already adapt their decisons to each patient and patient group. Policymakers are encouraged to adopt a similar approach because populations as well as particular market situations vary and therefore policy solutions cannot be considered universal.*This article is the second in a series of articles on this topic that will appear in Pharmacy World & Science during 2005.     

Applying health technology assessment to pharmaceutical care: pitfalls and future directions

It has been argued in previous issues of this journal that health technology assessment can be used as a tool to assess the efficiency of pharmaceutical care by linking its impact on clinical and humanistic outcomes to the resources required to achieve these outcomes. Additionally, as policy-makers appreciate the need to evaluate projects on the basis of their costs and benefits, the application of health technology assessment to pharmaceutical care may serve as a way of communicating with policy-makers and informing policy on pharmaceutical care.This article elaborates on this idea by arguing that policy-makers will be more likely to appreciate the value of pharmaceutical care if researchers pay more attention to some methodological principles underlying health technology assessment in the context of pharmaceutical care, and if they take into account the decision-making context facing policy-makers. In order to raise the methodological quality of studies, researchers need to take care to define better the pharmaceutical care intervention; to evaluate the costs of the intervention and its impact on the utilization of other health services; and to aggregate the various clinical and humanistic outcome measures that are commonly used in this type of research. In order to increase the usefulness of study findings to policy-makers, researchers need to identify the multiple objectives that policy-makers pursue, and show how study findings will aid policy-makers in attaining these objectives.